Shalee Nanney
Family · Greeneville, TNNPI 1578088464
Payments from drug & device makers
Across 342 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$759
- Novo Nordisk$714
- Lilly USA, LLC$459
- Bayer$267
- Novartis$214
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 86 | $1,049 |
| Pfizer | 51 | $759 |
| Novo Nordisk | 51 | $714 |
| Lilly USA, LLC | 30 | $459 |
| Bayer | 14 | $267 |
| Novartis | 12 | $214 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $202 |
| Amgen | 11 | $162 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $156 |
| GSK | 8 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $104 |
| Dexcom, Inc. | 4 | $95 |
| Boehringer Ingelheim | 6 | $92 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| AstraZeneca | 5 | $81 |
| Sumitomo Pharma America, Inc. | 5 | $74 |
| Phathom Pharmaceuticals, Inc. | 3 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Exact Sciences | 3 | $51 |
| Biohaven Pharmaceuticals, Inc. | 3 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Seqirus USA Inc | 2 | $40 |
| Johnson & Johnson | 3 | $39 |
| Merck | 2 | $39 |
| Corcept Therapeutics | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Teleflex LLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Intra-sana Laboratories | 1 | $13 |
How this compares
$5,176 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $101,945 |
| MounjaroTirzepatide | 59 | $68,551 |
| TrulicityDulaglutide | 47 | $46,687 |
| EliquisApixaban | 41 | $33,316 |
| JanuviaSitagliptin Phosphate | 35 | $31,487 |
| FarxigaDapagliflozin Propanediol | 24 | $24,543 |
| JardianceEmpagliflozin | 22 | $21,610 |
| QuliptaAtogepant | 13 | $15,505 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,921 |
| LinzessLinaclotide | 11 | $10,211 |
| MyrbetriqMirabegron | 13 | $9,050 |
| KerendiaFinerenone | 14 | $8,743 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,787 |
| Imipramine Pamoate | 11 | $3,050 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $459 | $115,237106 claims |
| Novo NordiskOzempic | $714 | $101,94595 claims |
| PfizerEliquis | $759 | $33,31641 claims |
| MerckJanuvia | $39 | $31,48735 claims |
| AbbVieQulipta, Linzess | $1,049 | $25,71724 claims |
| AstraZenecaFarxiga | $81 | $24,54324 claims |
| Boehringer IngelheimJardiance | $92 | $21,61022 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $134 | $17,84334 claims |
| BayerKerendia | $267 | $8,74314 claims |
| Sanofi-aventis U.S. LLCLantus | $40 | $1,21212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Greeneville
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.